BML Capital Management LLC Purchases 30,000 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

BML Capital Management LLC increased its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 20.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 180,000 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Verrica Pharmaceuticals makes up 1.0% of BML Capital Management LLC’s portfolio, making the stock its 18th largest holding. BML Capital Management LLC owned approximately 0.43% of Verrica Pharmaceuticals worth $1,318,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in Verrica Pharmaceuticals by 29.4% in the third quarter. FMR LLC now owns 1,504,716 shares of the company’s stock worth $5,846,000 after purchasing an additional 341,584 shares during the period. Jump Financial LLC bought a new position in Verrica Pharmaceuticals in the third quarter worth $71,000. Finally, Kovitz Investment Group Partners LLC raised its stake in Verrica Pharmaceuticals by 44.3% during the third quarter. Kovitz Investment Group Partners LLC now owns 50,125 shares of the company’s stock worth $195,000 after acquiring an additional 15,400 shares in the last quarter. 42.45% of the stock is owned by institutional investors.

Verrica Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:VRCA opened at $6.85 on Wednesday. Verrica Pharmaceuticals Inc. has a twelve month low of $2.86 and a twelve month high of $7.76. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.49 and a current ratio of 4.55. The business has a fifty day moving average of $5.72 and a 200-day moving average of $5.09.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Thursday, February 29th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Verrica Pharmaceuticals had a negative net margin of 1,307.47% and a negative return on equity of 119.46%. The business had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.10 million. Analysts forecast that Verrica Pharmaceuticals Inc. will post -1.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on VRCA shares. HC Wainwright increased their price objective on Verrica Pharmaceuticals from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Verrica Pharmaceuticals in a research note on Wednesday, April 10th.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.